NVO
HEALTHCARENovo Nordisk
AI Insight
What's Moving NVO Today?
No stock-specific AI insight has been generated for NVO yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$34.58$68.49
$50.56
Fundamentals
Market Cap$218.9B
P/E Ratio11.9
EPS$4.17
Dividend Yield3.64%
Dividend / Share$11.70
ROE71.4%
Profit Margin37.2%
Debt / Equity—
Trading
Volume10.3M
Avg Volume (10D)—
Shares Outstanding3.35B
NVO News
83 articles- Global Blood Glucose Monitoring System Market Size to Reach USD 39.4 Billion by 2035 | Growing at 8.9% CAGR | Industry Trends, Market Share & Forecast – Custom Market InsightsGlobeNewswire Inc.·Jul 14, 2026
- 3 Dividend Stocks That Are No-Brainer Buys Heading Into the Second Half of 2026Motley Fool·Jul 11, 2026
- Is Pfizer on Track to Launch Its Next Lipitor -- This Time in the Weight-Loss Market?Motley Fool·Jul 10, 2026
- No easy answers: European research consortia take on major challengesNovo Nordisk Fonden·Jul 10, 2026
- NVO Rallies 11% in a Month: How Should Investors Play the Stock?Yahoo Finance·Jul 10, 2026
- AI Revolutionizes Cardiovascular Drug Development with $1.4+ Billion in Strategic InvestmentsYahoo Finance·Jul 10, 2026
- Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should KnowYahoo Finance·Jul 10, 2026
- Here's Why Shares in Novo Nordisk Rival, Agios Pharmaceutical, Soared This WeekMotley Fool·Jul 10, 2026
- Record Numbers of Americans Are on GLP-1 Drugs. That's Great News for This Stock.Motley Fool·Jul 9, 2026
- Novo Nordisk (NVO) In Focus After Wegovy Label Update As Undervalued Narrative HoldsYahoo Finance·Jul 9, 2026
- Novo Nordisk (NYSE:NVO) Updates Wegovy Label In Singapore With STEP UP DataYahoo Finance·Jul 9, 2026
- Two Drugmakers Own 90% of the Obesity Boom. One Fund Owns Both for 0.59%247 Wall St·Jul 9, 2026
- Novo Nordisk (CPSE:NOVO B) Could Be 13% Overvalued Following Its Vivani DealYahoo Finance·Jul 9, 2026
- PRTA Stock Rises Nearly 11% in Six Months: What's Driving It?Yahoo Finance·Jul 9, 2026
- Buyout Buzz Around VKTX Is Back: What's Fueling the Speculation?Yahoo Finance·Jul 9, 2026
- 3 High Growth GLP-1 Biotech Winners to Buy in July247 Wall St·Jul 9, 2026
- Novo Nordisk launches weekly insulin Awiqli in India as diabetes burden risesReuters·Jul 9, 2026
- GLP-1 weight-loss drug popularity reaches new heights with AmericansThe Street·Jul 9, 2026
- Novo Nordisk (NVO) Dips More Than Broader Market: What You Should KnowYahoo Finance·Jul 8, 2026
- Novo Nordisk shares dip as latest prescription data points to GLP-1 pill slowdownProactive Investors·Jul 8, 2026
- LLY Hits Another Record High: Is the Stock Too Expensive to Buy Now?Yahoo Finance·Jul 8, 2026
- Leading bank backs European pharma as the cleaner alternative to the AI tradeProactive Investors·Jul 8, 2026
- Novo Nordisk signs pact with Vivani for long-lasting semaglutide implantPharmaceutical-technology·Jul 8, 2026
- How Much Could $1,000 Invested in Viking Therapeutics Be Worth by 2030?The Motley Fool·Jul 5, 2026
- Johnson & Johnson Is Walking Away From a $100 Billion Obesity Market. Could That Actually Make It the Better Long-Term Buy Than Eli Lilly?The Motley Fool·Jul 4, 2026
- Big Pharma Has a Case of Merger ManiaThe Motley Fool·Jun 30, 2026
- Opinion: Pfizer Is a Fantastic Dividend Stock for Income Investors to Buy Right NowThe Motley Fool·Jun 27, 2026
- Is Eli Lilly Stock an Undervalued Healthcare Stock to Buy?The Motley Fool·Jun 27, 2026
- Novo Nordisk to showcase new data across its hemophilia portfolio at the ISTH Congress 2026, featuring investigational denecimigYahoo Finance Singapore·Jun 26, 2026
- HIMS Stock Eyes Big Monthly Win: Novo Nordisk Calls Hims & Hers One Of Its Most ‘Voluminous’ Telehealth PartnersStocktwits·Jun 26, 2026
- Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?The Motley Fool·Jun 20, 2026
- Hacking ring seeks to extort Novo Nordisk after cyberattackpharmaphorum·Jun 17, 2026
- [Latest] Global GLP-1 Receptor Agonist Market Size/Share Worth USD 95.3 Billion by 2035 at a 12.1% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)GlobeNewswire Inc.·Jun 16, 2026
- 3 Reasons to Buy Eli Lilly Stock Like There's No TomorrowThe Motley Fool·Jun 14, 2026
- Is Viking Therapeutics Stock Going to $100?The Motley Fool·Jun 12, 2026
- Nxera Joins OpenFold AI Research Consortium Alongside Leading Global Pharmaceutical and AI Companies to Accelerate AI-enabled Drug DiscoveryGlobeNewswire Inc.·Jun 10, 2026
- Novo's Wegovy Pill Isn't Just Beating Expectations -- It's Obliterating Them. Is the Beaten-Down Stock a Buy Now?The Motley Fool·Jun 6, 2026
- Lilly's New Drug Just Delivered the Largest Weight Loss Ever Seen in a Clinical Trial -- Here's What It Means for InvestorsThe Motley Fool·May 30, 2026
- The Smartest Growth Stocks to Buy With $2,000 Right NowThe Motley Fool·May 30, 2026
- [Latest] Global Bioprocess Automation Software Market Size/Share Worth USD 6.19 Billion by 2035 at a 14 CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)GlobeNewswire Inc.·May 26, 2026
Price Data
Open$49.36
Previous Close$49.07
Day High$51.00
Day Low$49.36
52 Week High$68.49
52 Week Low$34.58
52-Week Range
$34.58$68.49
$50.56
Fundamentals
Market Cap$218.9B
P/E Ratio11.9
EPS$4.17
Dividend Yield3.64%
Dividend / Share$11.70
ROE71.4%
Profit Margin37.2%
Debt / Equity—
Trading
Volume10.3M
Avg Volume (10D)—
Shares Outstanding3.35B
About Novo Nordisk
Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.
HEALTHCAREDRUG MANUFACTURERS - GENERAL
Company Details
Security TypeStock
ExchangeNYSE
CurrencyUSD
Round Lot—
SICDRUG MANUFACTURERS - GENERAL
CIK—
Composite FIGI—
Share Class FIGI—